Brief: Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V.
Dec 12 (Reuters) - Genmab A/S GMAB.CO: GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD EXPECTS TO LAUNCH PETOSEMTAMAB IN 2027 INTENDS TO BROADEN AND ACCELERATE PETOSEMTAMAB'S DEVELOPMENT WITH POTENTIAL EXPANSION INTO OTHER LINES OF THERAPY BELIEVES THAT PETOSEMTAMAB WILL BE ACCRETIVE TO EBITDA WITH AT LEAST ONE-BILLION-DOLLAR ANNUAL SALES POTENTIAL BY 2029 94.2% OF MERUS SHARES TENDERED IN GENMAB'S OFFER Source text: ID:nGNE1tXd77 Further company coverage: GMAB.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss